Back to Top
  • Clinical OMICs is now Inside Precision Medicine!

    Driven by a rapid and exponentially growing market – one that is expected to be valued at more than $126 billion by 2025 – and our commitment to covering the full breadth of the revolutionary field of precision medicine, Clinical OMICs is now Inside Precision Medicine.


    Inside Precision Medicine will continue to deliver the critical, foundational coverage of Translational Research, Molecular Diagnostics, Informatics, Oncology, and Patient Care that subscribers rely on while expanding coverage into leading-edge, headline-driving topics like Payer and Regulatory issues, including insurance and reimbursement, regulatory review and approval, and data privacy and security.

Aims & Scope

Through its flagship Magazine, up-to-the-minute Website, suite of eNewsletters, and dynamic portfolio of broadcast events and multimedia, Inside Precision Medicine (formerly Clinical OMICs) is the only global media brand covering the full spectrum of precision medicine, taking a wide lens approach while bringing into sharp focus the many complex and interconnected issues that constitute the field.

From the core areas of Translational Research, Molecular Diagnostics, Informatics, and Patient Care to expanded coverage of Disease Indications and Payer/Regulatory issues, Inside Precision Medicine’s best-in-class content informs, educates, and enlightens our diverse audience of researchers, pathologists, clinicians, executives, and other professionals.

Inside Precision Medicine is a must-have title for institutions – the only publication that brings together into one premier resource the full scope of precision medicine to meet the information needs of users. A subscription provides immediate access to all new content, as well as at least five full years’ of archive content from Clinical OMICs.

Inside Precision Medicine coverage includes:

  • Translational Research
    • Biomarkers
    • Proteomics
    • Metabolomics
    • Microbiome
    • Genome-Wide Association Studies (GWAS)
  • Molecular Diagnostics
    • Oncology
    • Pharmacogenomics
    • NIPT (Non-Invasive Prenatal Testing)
    • Point of Care Diagnostics
    • CRISPR
  • Informatics
    • Big Data
    • Real-World Evidence/Data
    • EHR-Health Data Integration
    • Population Health
    • Artificial Intelligence
    • Wearables and Sensor
    • Data Capture
  • Disease Indications
    • Oncology
    • Immunotherapy
    • Targeted Therapies
    • Diagnostic/Therapy Co-Development
    • Digital Pathology
    • Therapy/Disease
    • Recurrence Monitoring
    • Cardiovascular, Neurodegenerative, and Metabolic Diseases
    • Rare Disease
  • Patient Care
    • Clinical Decision Support
    • Gene Therapy
    • Genetic Counseling
    • Wellness
    • Polygenic Risk Scores
    • Health Disparities
  • Payer/Regulatory
    • Private/Public Insurance
    • Regulatory Bodies
    • Clinical Trials
    • Data Privacy and Security
The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.